August 22, 2016
Fresenius Kabi is planning a $250-million expansion of the pharmaceutical company’s urban Chicago campus. The current Melrose Park site will be transformed into an advanced manufacturing site.
As many as four new buildings, totaling as much as 130,000 square feet, will be connected to the existing 124,267-square-foot plant. Groundbreaking is slated for next year, and completion is expected in 2026.
The campus will feature fully automated aseptic filling lines using state-of-the-art isolator technology, expanded freeze-drying capabilities, formulation areas, a dedicated warehouse for raw materials and components, and an administration building with conference center, labs, office space and cafeteria.
The global health care company specializes in life-saving medicines and technologies for infusion, transfusion and clinical nutrition. The German drug maker’s U.S. HQ is in Lake Zurich, IL.
For comments, questions or concerns, please contact Dennis Kaiser